Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study-Reference-Cited by-同舟云学术

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

Published:2019-08 Issue:8 Volume:14 Page:1390-1399
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Boothman Anne-Marie,Scott Marietta,Ratcliffe Marianne,Whiteley Jessica,Dennis Phillip A.,Wadsworth Catherine,Sharpe Alan,Rizvi Naiyer A.,Garassino Marina Chiara,Walker Jill

Funder

Pfizer

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Immunotherapy in previously treated non–small cell lung cancer (NSCLC);Leal;J Thorac Dis,2018

2. Immunotherapy in treatment naïve advanced non–small cell lung cancer;Ernani;J Thorac Dis,2018

3. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis;Abdel-Rahman;Crit Rev Oncol Hematol,2016

4. Anti–PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials;Zhou;Medicine (Baltimore),2016

5. Durvalumab as third-line or later treatment for advanced non–small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study;Garassino;Lancet Oncol,2018

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma;Frontiers in Oncology;2024-08-30

2. Differences in pathological diagnoses between bronchoscopic tissue and resected specimens of non-small cell lung cancer: A retrospective single center study;2024-08-10

3. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer;PLOS ONE;2024-07-31

4. Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report;Frontiers in Oncology;2024-07-08

5. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer;Cancer Treatment Reviews;2024-07